• linkedin
  • Increase Font
  • Sharebar

    Urologists positive about abiraterone integration

    96% find incorporating treatment easy or manageable after overcoming barriers


    Urologists must know potential side effects

    Urologists who integrate abiraterone into practice need to have a keen understanding of the drug’s mechanism of action and potential side effects.

    “These are not sort of ‘set-it-and-forget-it’ kind of drugs,” Dr. Feifer said.

    Abiraterone patients need monitoring and follow-up—often more than other patients in a urologist’s office, according to Dr. Feifer. Monitoring includes checking blood pressure, measuring liver function, and checking for weight gain. It also requires looking at oral dentition to make sure there’s no risk of osteonecrosis of the jaw.

    “Urologists also have to be aware of not sending the patients too late to the medical oncologist for further cytotoxic therapy,” he said. “The role of multidisciplinary care has to be enforced and really looked upon as an important tenet of care, because although urologists may be treating their patients with abiraterone acetate in their offices with safety and efficacy, waiting too long to broaden the scope of care to include an oncologist or radiation oncologist, where appropriate, is not in the best interest of the patient.”

    Read: Online information linked to PCa treatment regret

    The bottom line, according to Dr. Feifer, is that urologists within the community setting can very well increase their use of medications for metastatic castration-resistant prostate cancer, with safety and efficacy.

    “Patients with whom they maintain long-term relationships can still be their patients when they have reached the castrate-resistant stage, and the subsequent treatment of these patients is… entirely possible and doable,” he said.

    Dr. Feifer is a Janssen advisory board member and has received honoraria and travel, accomodations, and expenses from Janssen and Astellas Pharma. Several of his co-authors are consultants/advisers and/or employees of Janssen and/or have received honoraria from the company. Several co-authors have a financial or other relationship with other pharmaceutical companies. The current study was sponsored by Janssen.

    More from Urology Times:

    Embolization for BPH shows long-term safety, efficacy

    Pain most common reason for post-URS ED visits

    Pelvic floor PT improves pelvic pain, voiding symptoms

    Subscribe to Urology Times to get monthly news from the leading news source for urologists.

    Lisette Hilton
    Lisette Hilton is a writer in Boca Raton, Fla., who heads up her company, Words Come Alive.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available